medalphabetМедицинский алфавитMedical alphabet2078-56312949-2807ООО «Альфмед»10.33667/2078-5631-2022-12-38-40medalphabet-2678Research ArticleСтатьиПрименение противокислотной терапии в эпоху пандемии COVID-19: потенциальные плюсы и минусыUsing anti-acid therapy in era of COVID-19 pandemic: Potential pros and consАхмедовВ. А.AkhmedovV. A.

Ахмедов Вадим Адильевич, д.м.н., проф., зав. кафедрой медицинский реабилитации ДПО

г. Омск

Akhmedov Vadim A., DM Sci (habil.), professor, head of Dept of Medical Rehabilitation of Additional Professional Education

Omsk 

ФГБОУ ВО «Омский государственный медицинский университет» Минздрава РоссииРоссияOmsk State Medical UniversityRussian Federation202220062022012Практическая гастроэнтерология (1)3840Copyright © Ахмедов В.А., 20222022Ахмедов В.А.Akhmedov V.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-alphabet.com/jour/article/view/2678

В представленной обзорной статье показаны данные о том, что, несмотря на то что лечение ИПП может быть связано с повышенным риском заражения SARS-CoV-2, результаты последних исследований продемонстрировали отсутствие влияния текущего лечения ИПП на исход COVID-19, тем самым предполагая, что предыдущие противоречивые результаты были, вероятно, связаны с различиями в дизайне исследования и популяции. Попытки перевода пациентов с кислотоассоциированными заболеваниями на Н2- гистаминоблокаторы на фоне инфекции COVID-19 являются не совсем обоснованными, так как, несмотря на некоторые положительные аспекты в воздействии на вирус, стандартные терапевтические дозы препаратов для лечения гастроэзофагеальной рефлюксной болезни и других кислотоассоциированных заболеваний являются недостаточными для достижения клинического эффекта у этой категории пациентов.

This review articles shows evidence that while PPI treatment may be associated with an increased risk of SARS-CoV-2 infection, recent findings have shown no effect of current PPI treatment on COVID-19 outcome, suggesting that previous inconsistent results were likely due to differences in study design and population. Attempts to transfer patients with COVID-19 infection to H2 histamine blockers are not entirely justified, since despite some positive aspects in the effect on the virus, standard therapeutic doses of drugs for the treatment of gastroesophageal reflux disease and other acid-associated diseases are insufficient to achieve a clinical effect at this category of patients.

кислотоассоциированные заболеванияИППН2-гистаминоблокаторыCOVID-19лечение.acid-associated diseasesPPIsH2 histamine blockersCOVID-19treatment.ReferencesSavarino V., Marabotto E., Furnari M., Zingone F., Zentilin P., Savarino E. Latest insights into the hot question of proton pump inhibitor safety – a narrative review. Dig Liver Dis 2020; 52: 842–852.Savarino V., Marabotto E., Furnari M., Zingone F., Zentilin P., Savarino E. Latest insights into the hot question of proton pump inhibitor safety – a narrative review. Dig Liver Dis 2020; 52: 842–852.Sasaki T., Nakayama K., Yasuda H., Yamaya M. A new strategy with proton pump inhibitors for the prevention of acute exacerbations in COPD. Ther Adv Respir Dis 2011; 5: 91–103.Sasaki T., Nakayama K., Yasuda H., Yamaya M. A new strategy with proton pump inhibitors for the prevention of acute exacerbations in COPD. Ther Adv Respir Dis 2011; 5: 91–103.Savarino V., Dulbecco P., Savarino E. Are proton pump inhibitors really so dangerous? Dig Liver Dis 2016; 48: 851–859.Savarino V., Dulbecco P., Savarino E. Are proton pump inhibitors really so dangerous? Dig Liver Dis 2016; 48: 851–859.Namazi M. R., Jowkar F. A succinct review of the general and immunological pharmacologic effects of proton pump inhibitors. J Clin Pharm Ther 2008; 33: 215–217.Namazi M. R., Jowkar F. A succinct review of the general and immunological pharmacologic effects of proton pump inhibitors. J Clin Pharm Ther 2008; 33: 215–217.Charpiat B., Bleyzac N., Tod M. Proton Pump Inhibitors are Risk Factors for Viral Infections: Even for COVID-19? Clin Drug Investig 2020; 40: 897–899.Charpiat B., Bleyzac N., Tod M. Proton Pump Inhibitors are Risk Factors for Viral Infections: Even for COVID-19? Clin Drug Investig 2020; 40: 897–899.Eom C. S., Jeon C. Y., Lim J. W., Cho E. G., Park S. M., Lee K. S. Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis. CMAJ 2011; 183: 310–319.Eom C. S., Jeon C. Y., Lim J. W., Cho E. G., Park S. M., Lee K. S. Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis. CMAJ 2011; 183: 310–319.Luxenburger H., Sturm L., Biever P., Rieg S., Duerschmied D., Schultheiss M., Neumann-Haefelin C., Thimme R., Bettinger D. Treatment with proton pump inhibitors increases the risk of secondary infections and ARDS in hospitalized patients with COVID-19: coincidence or underestimated risk factor? J Intern Med 2021; 289: 121–124.Luxenburger H., Sturm L., Biever P., Rieg S., Duerschmied D., Schultheiss M., Neumann-Haefelin C., Thimme R., Bettinger D. Treatment with proton pump inhibitors increases the risk of secondary infections and ARDS in hospitalized patients with COVID-19: coincidence or underestimated risk factor? J Intern Med 2021; 289: 121–124.Heidelbaugh J. J. Proton pump inhibitors and risk of vitamin and mineral deficiency: evidence and clinical implications. Ther Adv Drug Saf 2013; 4: 125–133.Heidelbaugh J. J. Proton pump inhibitors and risk of vitamin and mineral deficiency: evidence and clinical implications. Ther Adv Drug Saf 2013; 4: 125–133.Henry E. B., Carswell A., Wirz A., Fyffe V., McColl K. E. Proton pump inhibitors reduce the bioavailability of dietary vitamin C. Aliment Pharmacol Ther 2005; 22: 539–545.Henry E. B., Carswell A., Wirz A., Fyffe V., McColl K. E. Proton pump inhibitors reduce the bioavailability of dietary vitamin C. Aliment Pharmacol Ther 2005; 22: 539–545.Feyaerts A. F., Luyten W. Vitamin C as prophylaxis and adjunctive medical treatment for COVID-19? Nutrition 2020; 79–80: 110948.Feyaerts A. F., Luyten W. Vitamin C as prophylaxis and adjunctive medical treatment for COVID-19? Nutrition 2020; 79–80: 110948.Srinutta T., Chewcharat A., Takkavatakarn K., Praditpornsilpa K., Eiam-Ong S., Jaber B. L., Susantitaphong P. Proton pump inhibitors and hypomagnesemia: A meta-analysis of observational studies. Medicine (Baltimore) 2019; 98: e17788.Srinutta T., Chewcharat A., Takkavatakarn K., Praditpornsilpa K., Eiam-Ong S., Jaber B. L., Susantitaphong P. Proton pump inhibitors and hypomagnesemia: A meta-analysis of observational studies. Medicine (Baltimore) 2019; 98: e17788.Кatopodis P., Karteris E., Katopodis K. P. Pathophysiology of Drug-Induced Hypomagnesaemia. Drug Saf 2020; 43: 867–880.Кatopodis P., Karteris E., Katopodis K. P. Pathophysiology of Drug-Induced Hypomagnesaemia. Drug Saf 2020; 43: 867–880.Thébault S., Cao G., Venselaar H., Xi Q., Bindels R. J., Hoenderop J. G. Role of the alpha-kinase domain in transient receptor potential melastatin 6 channel and regulation by intracellular ATP. J Biol Chem 2008; 283: 19999–20007.Thébault S., Cao G., Venselaar H., Xi Q., Bindels R. J., Hoenderop J. G. Role of the alpha-kinase domain in transient receptor potential melastatin 6 channel and regulation by intracellular ATP. J Biol Chem 2008; 283: 19999–20007.Voets T., Nilius B., Hoefs S., van der Kemp A. W., Droogmans G., Bindels R. J., Hoenderop J. G. TRPM6 forms the Mg2+ influx channel involved in intestinal and renal Mg2+ absorption. J Biol Chem 2004; 279: 19–25.Voets T., Nilius B., Hoefs S., van der Kemp A. W., Droogmans G., Bindels R. J., Hoenderop J. G. TRPM6 forms the Mg2+ influx channel involved in intestinal and renal Mg2+ absorption. J Biol Chem 2004; 279: 19–25.Uwitonze A. M., Razzaque M. S. Role of Magnesium in Vitamin D Activation and Function. J Am Osteopath Assoc 2018; 118: 181–189.Uwitonze A. M., Razzaque M. S. Role of Magnesium in Vitamin D Activation and Function. J Am Osteopath Assoc 2018; 118: 181–189.Ali N. Role of vitamin D in preventing of COVID-19 infection, progression and severity. J Infect Public Health 2020; 13: 1373–1380.Ali N. Role of vitamin D in preventing of COVID-19 infection, progression and severity. J Infect Public Health 2020; 13: 1373–1380.Hariyanto T. I., Prasetya I. B., Kurniawan A. Proton pump inhibitor use is associated with increased risk of severity and mortality from coronavirus disease 2019 (COVID-19) infection. Dig Liver Dis 2020; 52: 1410–1412.Hariyanto T. I., Prasetya I. B., Kurniawan A. Proton pump inhibitor use is associated with increased risk of severity and mortality from coronavirus disease 2019 (COVID-19) infection. Dig Liver Dis 2020; 52: 1410–1412.Israelsen S. B., Ernst M. T., Lundh A., Lundbo L. F., Sandholdt H., Hallas J., Benfield T. Proton Pump Inhibitor Use Is Not Strongly Associated With SARS-CoV-2 Related Outcomes: A Nationwide Study and Meta-analysis Clin Gastroenterol Hepatol. 2021 Sep; 19 (9): 1845–1854.Israelsen S. B., Ernst M. T., Lundh A., Lundbo L. F., Sandholdt H., Hallas J., Benfield T. Proton Pump Inhibitor Use Is Not Strongly Associated With SARS-CoV-2 Related Outcomes: A Nationwide Study and Meta-analysis Clin Gastroenterol Hepatol. 2021 Sep; 19 (9): 1845–1854.Taştemur Ş., Ataseven H. Is it possible to use Proton Pump Inhibitors in COVID-19 treatment and prophylaxis? Med Hypotheses 2020; 143: 110018.Taştemur Ş., Ataseven H. Is it possible to use Proton Pump Inhibitors in COVID-19 treatment and prophylaxis? Med Hypotheses 2020; 143: 110018.Ray A., Sharma S., Sadasivam B. The Potential Therapeutic Role of Proton Pump Inhibitors in COVID-19: Hypotheses Based on Existing Evidences. Drug Res (Stuttg) 2020; 70: 484–488.Ray A., Sharma S., Sadasivam B. The Potential Therapeutic Role of Proton Pump Inhibitors in COVID-19: Hypotheses Based on Existing Evidences. Drug Res (Stuttg) 2020; 70: 484–488.Ghebre Y., Raghu G. Proton pump inhibitors in IPF: beyond mere suppression of gastric acidity. QJM 2016; 109: 577–579.Ghebre Y., Raghu G. Proton pump inhibitors in IPF: beyond mere suppression of gastric acidity. QJM 2016; 109: 577–579.Freedberg D. E., Conigliaro J., Wang T. C., Tracey K. J., Callahan M. V., Abrams J. A. Famotidine use is associated with improved clinical outcomes in hospitalized COVID-19 patients: a propensity score matched retrospective cohort study. Gastroenterology 2020;159: 1129–1131.Freedberg D. E., Conigliaro J., Wang T. C., Tracey K. J., Callahan M. V., Abrams J. A. Famotidine use is associated with improved clinical outcomes in hospitalized COVID-19 patients: a propensity score matched retrospective cohort study. Gastroenterology 2020;159: 1129–1131.Mather J. F., Seip R. L., McKay R. G. Impact of famotidine use on clinical outcomes of hospitalized patients with COVID-19. Am J Gastroenterol. 2020; 115: 1617–1623.Mather J. F., Seip R. L., McKay R. G. Impact of famotidine use on clinical outcomes of hospitalized patients with COVID-19. Am J Gastroenterol. 2020; 115: 1617–1623.Shoaibi A., Fortin S., Weinstein R., Berlin J., Ryan P. Comparative efectiveness of famotidine in hospitalized COVID-19 patients. medRxiv. 2020.Shoaibi A., Fortin S., Weinstein R., Berlin J., Ryan P. Comparative efectiveness of famotidine in hospitalized COVID-19 patients. medRxiv. 2020.Mehta P., McAuley D.F., Brown M., Sanchez E., Tattersall R. S., Manson J. J. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020; 395: 1033–1034.Mehta P., McAuley D.F., Brown M., Sanchez E., Tattersall R. S., Manson J. J. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020; 395: 1033–1034.Anand K., Ziebuhr J., Wadhwani P., Mesters J. R., Hilgenfeld R. Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs. Science 2003; 300: 1763–1767.Anand K., Ziebuhr J., Wadhwani P., Mesters J. R., Hilgenfeld R. Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs. Science 2003; 300: 1763–1767.Birch C A, Molinar-Inglis O., Trejo J. Subcellular hot spots of GPCR signaling promote vascular inflammation. Curr Opin Endocr Metab Res 2021; 16: 37–42.Birch C A, Molinar-Inglis O., Trejo J. Subcellular hot spots of GPCR signaling promote vascular inflammation. Curr Opin Endocr Metab Res 2021; 16: 37–42.Krystel-Whittemore M., Dileepan K. N., Wood J. G. Mast cell: a multi-functional master cell. Front Immunol. 2016; 6: 620.Krystel-Whittemore M., Dileepan K. N., Wood J. G. Mast cell: a multi-functional master cell. Front Immunol. 2016; 6: 620.Hogan Ii R. B., Hogan Iii R. B., Cannon T., Rappai M., Studdard J., Paul D., Dooley T. B. Dual-histamine receptor blockade with cetirizine – famotidine reduces pulmonary symptoms in COVID-19 patients. Pulm Pharmacol Ther. 2020; 63: 101942.Hogan Ii R. B., Hogan Iii R. B., Cannon T., Rappai M., Studdard J., Paul D., Dooley T. B. Dual-histamine receptor blockade with cetirizine – famotidine reduces pulmonary symptoms in COVID-19 patients. Pulm Pharmacol Ther. 2020; 63: 101942.

The authors declare that there are no conflicts of interest present.